{"id":60445,"date":"2024-08-22T00:35:43","date_gmt":"2024-08-21T22:35:43","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=60445"},"modified":"2024-08-21T13:56:38","modified_gmt":"2024-08-21T11:56:38","slug":"vybusna-studie-48-200-zdravotnickych-pracovniku-ukazuje-cim-vice-davek-vakciny-covid-19-mrna-tim-vyssi-je-riziko-infekce","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2024\/08\/22\/vybusna-studie-48-200-zdravotnickych-pracovniku-ukazuje-cim-vice-davek-vakciny-covid-19-mrna-tim-vyssi-je-riziko-infekce\/","title":{"rendered":"V\u00fdbu\u0161n\u00e1 studie: 48 200 zdravotnick\u00fdch pracovn\u00edk\u016f ukazuje \u2013 \u010d\u00edm v\u00edce d\u00e1vek vakc\u00edny COVID-19 mRNA, t\u00edm vy\u0161\u0161\u00ed je riziko infekce"},"content":{"rendered":"
<\/div>\n
\n
\n

Nabin Shrestha, MD, MPH<\/a>\u00a0, specialista na infek\u010dn\u00ed onemocn\u011bn\u00ed, a jeho kolegov\u00e9 z Clevelandsk\u00e9 kliniky prov\u00e1d\u011bli prob\u00edhaj\u00edc\u00ed studie se zdravotnick\u00fdmi pracovn\u00edky b\u011bhem pandemie COVID-19. V p\u0159edchoz\u00edch studi\u00edch zjistili, \u017ee v n\u011bkter\u00fdch p\u0159\u00edpadech, \u010d\u00edm \u010dast\u011bji byli \u00fa\u010dastn\u00edci o\u010dkov\u00e1ni mRNA vakc\u00ednami COVID-19, t\u00edm byli n\u00e1chyln\u011bj\u0161\u00ed k infekc\u00edm. V t\u00e9to nejnov\u011bj\u0161\u00ed studii publikovan\u00e9 v \u010dasopise Clinical Infectious Diseases t\u00fdm Cleveland Clinic zkoumal obecnou schopnost mRNA vakc\u00edny COVID-19 chr\u00e1nit p\u0159ed COVID-19.<\/strong><\/p>\n

Auto\u0159i op\u011bt prospektivn\u011b zkoumali kumulativn\u00ed v\u00fdskyt COVID-19 b\u011bhem n\u00e1sleduj\u00edc\u00edch 17 t\u00fddn\u016f o\u010dkov\u00e1n\u00edm \u00fa\u010dastn\u00edk\u016f mRNA vakc\u00ednou COVID-19 v letech 2023-2024. K anal\u00fdze skute\u010dn\u00e9 ochrany p\u0159ed vakcinac\u00ed COVID-19 mRNA jako \u010dasov\u011b z\u00e1visl\u00e9 kovariance l\u00e9ka\u0159i Cleveland Clinic pou\u017eili Coxovu regresi proporcion\u00e1ln\u00edch rizik, ve kter\u00e9 \u010dasov\u011b z\u00e1visl\u00e9 koeficienty odr\u00e1\u017eej\u00ed \u00fa\u010dinky p\u0159ed a po dominanci JN.1 linka odd\u011blena. Dr. Shrestha a jeho kolegov\u00e9 tak\u00e9 pova\u017eovali za kl\u00ed\u010dov\u00e9 prom\u011bnn\u00e9 ochotu nechat se testovat, v\u011bk, pohlav\u00ed, f\u00e1zi pandemie, ve kter\u00e9 do\u0161lo k posledn\u00ed epizod\u011b COVID-19, a po\u010det p\u0159edchoz\u00edch d\u00e1vek vakc\u00edny.<\/span><\/p>\n

jak\u00e9 byly v\u00fdsledky? Clevelandsk\u00e1 klinika dosp\u011bla k z\u00e1v\u011bru, \u017ee dosp\u011bl\u00ed v produktivn\u00edm v\u011bku zam\u011bstnan\u00ed klinikou Cleveland, kte\u0159\u00ed se \u00fa\u010dastnili t\u00e9to studie, poskytovali nejl\u00e9pe skromnou ochranu proti p\u0159evl\u00e1daj\u00edc\u00edmu \u0161\u00ed\u0159en\u00ed JN.1 pomoc\u00ed vzorce mRNA COVID-19 2023\u20132024 a pot\u00e9 nez\u00edskali optim\u00e1ln\u00ed ochranu. TrialSite informoval o t\u00e9to studijn\u00ed skupin\u011b a jej\u00edch v\u00fdsledc\u00edch, kter\u00e9 byly nyn\u00ed znovu potvrzeny \u2013 riziko infekce COVID-19 se zvy\u0161uje s po\u010dtem podan\u00fdch d\u00e1vek vakc\u00edny COVID-19 mRNA.<\/span><\/p>\n

V\u00fdsledek<\/strong><\/span><\/p>\n

Auto\u0159i studie, kter\u00e9 se z\u00fa\u010dastnilo 48 210 zam\u011bstnanc\u016f Cleveland Clinic, nahl\u00e1sili b\u011bhem 17t\u00fddenn\u00edho pozorovac\u00edho obdob\u00ed celkem 2 462 (5,1 %) p\u0159\u00edpad\u016f COVID-19. P\u0159i v\u00fdpo\u010dtu v\u00edcerozm\u011brn\u00e9 anal\u00fdzy Dr. Shrestha a jeho t\u00fdm zjistili, \u017ee stav o\u010dkov\u00e1n\u00ed podle vzorce 2023\u20132024 byl spojen s v\u00fdrazn\u011b ni\u017e\u0161\u00edm rizikem COVID-19, ne\u017e se linie JN.1 stala dominantn\u00ed (pom\u011br rizika = 0,58; 95% interval spolehlivosti [CI] = 0,49 -,68 P <,001) a s ni\u017e\u0161\u00edm rizikem, kter\u00e9 v\u0161ak ji\u017e nedos\u00e1hlo statistick\u00e9 v\u00fdznamnosti (pom\u011br rizika = ,81; 95% CI = ,65-1,01; P =,06).<\/span><\/p>\n

Clevelandsk\u00e1 klinika<\/strong><\/span><\/p>\n

\n
\"\"<\/figure>\n<\/div>\n

S odhadovanou \u00fa\u010dinnost\u00ed vakc\u00edny 42 % (95% CI = 32-51) p\u0159edt\u00edm, ne\u017e se linie JN.1 stala p\u0159evl\u00e1daj\u00edc\u00ed, toto \u010d\u00edslo po vzniku linie JN.1 rychle kleslo na 19 % (95% CI = -1). -35) a dokonce se dostaly do negativn\u00edho rozmez\u00ed jako v p\u0159edchoz\u00edch studi\u00edch.<\/span><\/p>\n

Nen\u00ed divu, \u017ee lid\u00e9 d\u0159\u00edve infikovan\u00ed kmenem XBB nebo nov\u011bj\u0161\u00edm kmenem SARS-CoV-2 m\u011bli ni\u017e\u0161\u00ed riziko infekce. Stejn\u011b jako v p\u0159edchoz\u00edch studi\u00edch riziko infekce COVID-19 \u201ese zv\u00fd\u0161ilo s po\u010dtem d\u00e1vek vakc\u00edny d\u0159\u00edve obdr\u017een\u00fdch\u201c.<\/span><\/p>\n

Tato nejnov\u011bj\u0161\u00ed studie, nyn\u00ed recenzovan\u00e1 a publikovan\u00e1 v respektovan\u00e9m \u010dasopise (p\u0159edchoz\u00ed studie byly pouze preprinty), je p\u0159evratn\u00fdm odhalen\u00edm, kter\u00e9 by nem\u011blo b\u00fdt ignorov\u00e1no.<\/span><\/p>\n

Omezen\u00ed<\/strong><\/span><\/p>\n

Jako v\u0161echny observa\u010dn\u00ed studie, i tato studie mus\u00ed b\u00fdt ch\u00e1p\u00e1na v kontextu jej\u00edch omezen\u00ed. Nap\u0159\u00edklad, a\u010dkoli skupina studovala tuto velkou kohortu zdravotnick\u00fdch pracovn\u00edk\u016f po celou dobu pandemie, jedn\u00edm ze z\u00e1kladn\u00edch p\u0159edpoklad\u016f Coxova modelu proporcion\u00e1ln\u00edch rizik je, \u017ee \u00fa\u010dinek dan\u00e9 kovari\u00e1ty se v pr\u016fb\u011bhu \u010dasu nem\u011bn\u00ed. Studie nestanovuje kauzalitu, ale sp\u00ed\u0161e poukazuje na korelaci.<\/span><\/p>\n

Vedouc\u00ed v\u00fdzkumu\/vy\u0161et\u0159ovatel<\/span><\/strong><\/h2>\n